News Novartis taps China's Abogen for autoimmunity TCE Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
News MSD, Moderna skin cancer vaccine scores historic phase 3 win Strong phase 3 results for Moderna's individualised skin cancer vaccine could pave the way for a leap forward in the field.
News FDA clears Moderna's mRNA-based seasonal flu shot After a series of regulatory twists and turns, the FDA has approved Moderna's mRNA-based influenza vaccine mFlusiva.
News Moderna starts first trial of its Bundibugyo Ebola vaccine Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus, as the outbreak in DRC gathers pace.
News Moderna's Q1 revenues rocket, thanks to ex-US sales Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
Event Partner Content 6th mRNA‑Based Therapeutics Summit Advancing mRNA's Therapeutic Potential to Combat All Diseases
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.